



**ASX Announcement**

**22<sup>nd</sup> July 2024**

## **Atomo Investor Webinar Presentation**

SYDNEY Australia, 22 July 2024 –Atomo Diagnostics Limited (ASX: **AT1**) (**Atomo** or the **Company**) will release its Q4 FY24 Results on Thursday, 25th July 2024.

A results briefing webinar for analysts and investors, hosted by Managing Director & CEO, John Kelly will be held on Thursday, 25th July 2024 at 11.00am (AEST).

To access the webinar please pre-register by clicking [this link](#).

Please submit any questions in advance of the webinar commencing to:  
[investorqueries@atomodiagnostics.com](mailto:investorqueries@atomodiagnostics.com)

~ ENDS ~

**For more information, please contact:**

**John Kelly**  
Managing Director & CEO  
e. [john.kelly@atomodiagnostics.com](mailto:john.kelly@atomodiagnostics.com)  
p. +61 401 922 279

**Investor Queries**  
[investorqueries@atomodiagnostics.com](mailto:investorqueries@atomodiagnostics.com)

*This announcement was authorised by the Managing Director & CEO.*

### **About Atomo**

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at [www.atomodiagnostics.com](http://www.atomodiagnostics.com)